Compare Redwire Corporation (RDW) vs 10X Genomics Inc (TXG) Price & Performance

RDW trades at $11.23, up 6.65% in the past 24 hours, with a bullish technical signal from moving averages and support near $11. The company reported Q2 2026 revenue growth of 90% year-over-year to $117.1 million and a record backlog of $542 million, but continues to post net losses, with a net income margin of -57.26% in 2026. Recent news highlights strategic investments in phased-array antenna technology and positive analyst sentiment with an 80% buy rating.

The stock offers growth potential driven by defense and space sector tailwinds and a expanding backlog, but high cash burn, persistent losses, and premium valuation (P/S of 4.59) pose significant risks. Execution on contracts and path to profitability are critical for sustaining the current bullish analyst outlook and price target of $12.17.

TXG trades at $65.60, up 4.71% today, with a bullish technical signal and recent earnings beats. The stock shows improving fundamentals, with 2025 revenue at $642.82M and net loss narrowing to -$43.54M. Positive sentiment is driven by patent wins, Atera platform demand, and institutional interest, though valuation metrics like P/S of 13.58 and EV/EBITDA of 142.2 remain elevated.

Outlook is cautiously optimistic with upside potential from Atera execution, but risks include high valuation, persistent losses, and competitive pressures. Analyst consensus is mixed with a $50.56 price target below current levels, indicating near-term caution despite long-term growth prospects in genomics.